Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4456 Characteristics and clinical outcomes after endoscopic or surgical resection of localised sporadic type III gastric NETs: A national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network

Introduction: Type III gastric neuroendocrine tumours (gNETs) are rare indolent tumours with increasing incidence. Endoscopic resection has recently been described to be a safe strategy to remove small, localised type III gNETs.

Conference:

Presenting Author: Perrier M

Authors: Perrier M, Lefort R, Do Cao C, Hautefeuille V, Wallenhorst T,

Keywords: neuroendocrine neoplasm, stomach, endoscopy, surgery, carcinoid,

#4027 Prognostic impact of molecular signatures in pancreatic metastatic neuroendocrine tumors (PRODETEN)

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are an heterogenous group of tumors. This heterogeneity is not explained by the main known prognostic factors (extension, evolution slope and Ki67 index). New molecular biomarkers (ARX, ATRX, DAXX, menin, PDX1) seem promising in non-metastatic PNENs.

Conference:

Presenting Author: de Mestier L

Authors: Pokossy Epee J, Cros J, Cadiot G, Do Cao C, Hautefeuille V,

Keywords: pancreas, neuroendocrine, prognostic, ATRX, daxx, arx, pdx1, Super Learner, menin, biomarker,

#3420 Etoposide-based rechallenge and second/third line treatments in patients with metastatic neuroendocrine carcinoma: Results from the multicenter RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

Introduction: Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line (SL) have not been studied.

Conference:

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Walter T, Hescot S, Hautefeuille V,

Keywords: Neuroendocrine carcinoma, Rb, rechallenge,

#3220 OPERA: Observational study of perception of information and quality of life (QoL) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) starting Lanreotide Autogel (LAN)

Introduction: The perception of information provided to patients with cancer upon diagnosis may influence adherence to treatment and QoL, but data are scarce in GEP-NETs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Walter T, Do Cao C, Coriat R, Dominguez S,

Keywords: somatostatin analogues, quality of life, QLQINFO25, QLQC30, gastroenteropancreatic neuroendocrine tumor,

#3136 Prognosis and the role of Rb expression in metastatic grade 3 neuroendocrine carcinoma (G3NEC), results from the multicenter retrospective RbNEC study

Introduction: Rb has been suggested to be a predictive/prognostic factor in G3NEC in which platinum etoposide (PE) is the first line treatment whatever primary.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V,

Keywords: neuroendocrine carcinoma, g3, Rb, prognosis,